suramin / Zhejiang University - LARVOL DELTA

Suramin blocked hCAP18/LL-37-induced macrophage recruitment and M2 polarization to enhance the therapeutic efficacy of 1,25(OH)2D3 against hepatocellular carcinoma in vitro and in vivo mouse model (Frontiers) - "1,25(OH)₂D₃ (200–500 nM) promoted macrophage recruitment, M2 polarization, Akt/mTOR signal and STAT3 signal activation in HCC/macrophage co-culture systems. This effect was mediated by 1,25(OH)₂D"

Preclinical • Hepatocellular Cancer

Phase I, Single-Dose Study to Assess the Pharmacokinetics and Safety of Suramin in Healthy Chinese Volunteers. (PubMed, Drug Des Devel Ther) - "Treatment-emergent adverse events (TEAEs) were generally mild in severity. The PK and safety profiles of suramin in Chinese subjects indicated that 10 mg/kg or 15 mg/kg could be an appropriate dose in a future multiple-dose study."

Journal • PK/PD data • Infectious Disease • Oncology

An Update on African Trypanocide Pharmaceutics and Resistance. (PubMed, Front Vet Sci) - "Suramin sodium suppresses ATP generation during the glycolytic pathway and is ineffective against T. vivax and T. congolense infections. In humans, the development of resistance and adverse side effects against monotherapies has led to the adoption of nifurtimox-eflornithine combination therapy. Current efforts to develop new prodrug combinations of nifurtimox and eflornithine and nitroimidazole fexinidazole as well as benzoxaborole SCYX-7158 (AN5568) for HAT are in progress while little comparable progress has been done for the development of novel therapies to address trypanocide resistance in AAT."

Journal • Review • Infectious Disease